Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Ovarian highlights from ESMO 2019

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Dr Marina Garassino - National Tumour Institute, Milan, Italy
Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )
28 Sep 2019

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )
28 Sep 2019

Comment: Osimertinib for EGFR-mutation positive NSCLC

Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain
Comment: Osimertinib for EGFR-mutation positive NSCLC ( Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain )
28 Sep 2019

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients

Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA
Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )
25 Sep 2019

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019

HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
25 Sep 2019

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients

Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK
Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK )
25 Sep 2019

First results of the GMMG-CONCEPT trial for multiple myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany
First results of the GMMG-CONCEPT trial for multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
25 Sep 2019

Iberdomide in combination with dexamethasone for multiple myeloma

Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA
Iberdomide in combination with dexamethasone for multiple myeloma ( Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA )
25 Sep 2019